Collectively, the preclinical pharmacology and toxicology data indicate CUSP06 could be an effective therapeutic to treat CDH6-positive human cancers, and a phase 1 study in ovarian cancer and other advanced solid tumors is ongoing (NCT06234423). Here, CDH6 is linked to cancer.